The latest price target for Mainz Biomed (NASDAQ:MYNZ) was reported by Cantor Fitzgerald on April 12, 2024. The analyst firm set a price target for $0.00 expecting MYNZ to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Mainz Biomed (NASDAQ:MYNZ) was provided by Cantor Fitzgerald, and Mainz Biomed reiterated their neutral rating.

There is no last upgrade for Mainz Biomed

The last downgrade for Mainz Biomed NV happened on November 21, 2023 when Cantor Fitzgerald changed their price target from N/A to N/A for Mainz Biomed NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mainz Biomed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mainz Biomed was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.

While ratings are subjective and will change, the latest Mainz Biomed (MYNZ) rating was a reiterated with a price target of $0.00 to $0.00. The current price Mainz Biomed (MYNZ) is trading at is $0.27, which is out of the analyst’s predicted range.